Rozbeh Jafari

Rozbeh Jafari

Senior Research Specialist | Docent
Visiting address: SciLifeLab, Tomtebodavägen 23A, 17121 Solna
Postal address: K7 Onkologi-Patologi, K7 Forskning Lehtiö, 171 77 Stockholm

About me

  • Dr. Jafari obtained his PhD in biomedical sciences at the department of chemistry and biomedical sciences, Karlstad University, where he developed antibody fragments for cancer immunotherapy of solid tumors. As a postdoc with Prof. Pär Nordlund at the department of biochemistry and biophysics, Karolinska Institutet, he developed the Cellular Thermal Shift Assay (CETSA) and its proteome wide adaptation, Thermal Proteome Profiling (TPP) and studied target and off-target identification and interaction of oncology drugs. He was awarded a assistant professor position from Swedish Childhood Fund in 2016 and the starting grant from Swedish Research Council in 2017 to establish his own research group at the department of oncology-pathology at Karolinska Institutet to apply multi-omic analysis of leukemias. In Feb 2024 he was accepted as Associate Professor in cell and molecular biology at the department of onkologi-patologi.


  • We are using and combining state of the art omics methods to obtain detailed pictures of the molecular phenotype of childhood and adult acute lymphoblastic leukemia to identify precision medicine candidates for improved therapy. One fundamental question we currently are trying to address is how cancer genome aberrations influence the functional proteome by combining genomics with proteomics data. This field is known as cancer proteogenomics. In addition to quantitative proteomics we are adding an additional layer of information by capturing the biophysical state of the proteome regardless of its abundance using thermal proteomics which also allows us to identify functional proteoforms with associations to drug sensitivity. We are also investigating the target landscape of current and emerging targeted therapeutics using orthogonal chemical proteomics approaches in order to understand their mechanism of action as well as their potential toxicities.

Selected publications


All other publications


  • Integrative multi-omics for mechanistic insights into acute lymphoblastic leukemia for precision therapies
    The Swedish Cancer Society
    1 January 2024 - 31 December 2026
  • Predictive therapeutic and resistance biomarkers in childhood leukemia using chemical proteomics
    The Swedish Childhood Cancer Fund
    1 January 2017 - 31 December 2019
  • Predictive therapeutic and resistance biomarkers in childhood leukemia using chemical proteomics
    The Swedish Childhood Cancer Fund
    1 September 2016 - 31 August 2021


  • Senior Research Specialist, Department of Oncology-Pathology, Karolinska Institutet, 2022-

Degrees and Education

  • Docent, Department of Oncology-Pathology, Karolinska Institutet, 2024
  • PhD, Department of Chemistry and Biomedical Sciences, Karlstad University, 2010

News from KI

Events from KI